Your Patients Are Not a Revenue Stream: The Frightening Business of Outsourced Peptide Medicine
Peptide and weight-management companies are increasingly approaching gyms, wellness businesses and medical practices with a simple proposition. Refer patients or members to an outside medical team, let that team handle the prescribing and pharmacy coordination, and receive a share of the resulting revenue.
There are legitimate ways for medical practices to work with outside clinicians, pharmacies and telehealth providers. There are also legitimate uses for compounded medications. But when treatment begins as a business-development opportunity rather than as the result of a medical evaluation, there are questions worth asking about prescribing standards, pharmacy sourcing, continuity of care, financial conflicts and patient safety.
A medical license and a prescription matter. Neither, by itself, tells us whether a particular treatment is evidence-based, appropriately sourced or right for the patient.
HormoneSynergy Clinic recently received an unsolicited sales email offering physician-managed peptide and weight-loss treatments through an outside medical team. The company would take care of consultations, prescribing, regulatory compliance and pharmacy coordination. We would introduce our “members” to the program and, according to the email, receive an additional revenue stream for the “gym.”
HormoneSynergy is not a gym, which made the pitch feel unusually generic. The more important issue, however, was the business model itself. Medical treatment was being presented to us partly as a referral-income opportunity.
That deserves scrutiny. Peptides include well-established medicines such as insulin and FDA-approved GLP-1 drugs, but the term is also used to market substances with limited human evidence, uncertain long-term safety or unresolved regulatory questions. Compounded medications can serve legitimate patient-specific needs, but they are not FDA-approved products and require careful attention to the prescriber, pharmacy, ingredient source, dosing and follow-up.
There is nothing inherently wrong with telehealth, compounding or outside referral relationships. The problem comes when the commercial arrangement begins driving the medical decision. Treatment should start with the patient and the clinical problem in front of us.
Editorial Transparency: This article was prompted by an unsolicited marketing email received by HormoneSynergy Clinic. We have not identified the sender or company because the purpose of this article is to examine the broader business model, not to make allegations about one particular organization.
“An Additional Revenue Stream for the Gym”
The solicitation offered “physician-managed peptide and weight-management treatments” through an outside licensed medical team.
According to the email, the outside company would handle:
- Patient consultations
- Prescribing
- Regulatory compliance
- Pharmacy coordination
Our part was apparently much simpler. We would introduce the program to our “members,” and the arrangement would create “an additional revenue stream for the gym.”
The description caught our attention immediately because HormoneSynergy Clinic is a physician-led preventive longevity medicine practice, not a gym. A quick look at our website would have made that clear.
That mistake was careless, but it was not the part that mattered most.
The larger concern was that a medical program involving prescription medications was being introduced to us as a way to generate referral income. We knew nothing about the clinicians, the depth of the medical evaluation, the pharmacies involved or how ongoing care would be handled.
Outside medical partnerships are not inherently inappropriate. Neither are referral relationships. But the clinical reason for referring a patient should be stronger than the financial reason for making the referral.
A Prescription Tells Us Only Part of the Story
The phrase “licensed medical team” sounds reassuring, and licensing is important. It establishes that someone has legal authority to practice within the scope allowed by that license.
It does not answer many of the questions that matter to the patient.
- Was there a meaningful medical evaluation?
- Is the proposed treatment supported by credible human evidence?
- Were contraindications, medical history and drug interactions reviewed?
- Does the prescriber have appropriate experience with the condition being treated?
- Which pharmacy is dispensing the medication?
- Where did the active ingredient come from?
- How are sterility, potency and stability addressed?
- Who follows the patient after the prescription is written?
- Who manages complications or side effects?
- Is anyone being paid because the patient was directed into the program?
Telehealth can provide excellent medical care. Compounding pharmacies can meet legitimate patient-specific needs. A physician may also have good reason to involve an outside specialist or treatment center.
The quality of care depends on how those services are used. Moving the prescription online does not lower the standard that should apply to the medical decision behind it.
“Peptide Therapy” Covers a Very Wide Range of Medicine
The word peptide has become a marketing category, particularly in longevity, weight loss and performance medicine. Medically, it is far less useful as a blanket description of whether a treatment works.
Peptides are short chains of amino acids. Some occur naturally in the body, and several have become important medicines. Insulin is a peptide hormone. Several FDA-approved GLP-1 receptor agonists are peptide-based medications with extensive clinical research behind them.
At the other end of the spectrum are peptides promoted for injury recovery, muscle growth, fat loss, cognition, inflammation and anti-aging despite much thinner human evidence. In some cases, most of what is being discussed comes from laboratory studies, animal research or anecdotal experience rather than controlled human trials.
That distinction can disappear quickly in online discussions, where everything gets grouped together under the same appealing label of “peptide therapy.”
In July 2026, an FDA advisory committee recommended that several controversial peptide substances be considered for inclusion on the federal list of substances that may be used under certain traditional compounding circumstances. That recommendation was advisory. It did not turn those substances into FDA-approved drugs or establish that they are safe and effective for the many uses being promoted online.
A substance may therefore be discussed, prescribed or compounded under certain circumstances without having the level of evidence people sometimes assume comes with those words.
Where Did the Medication Come From?
With an injectable medication, source is not a minor detail.
There is a meaningful difference between:
- An FDA-approved medication manufactured under an approved drug application
- A patient-specific compounded medication prepared by an appropriately licensed 503A pharmacy
- A medication supplied by a 503B outsourcing facility under applicable federal requirements
- A product labeled “for research use only”
- A substance purchased from an overseas supplier or gray-market website
They should not be treated as though they are equivalent simply because the vial contains the same name on the label.
Products sold online as research chemicals may not be legal medications intended for human treatment. A professional-looking website, laboratory-style packaging or posted certificate of analysis cannot, by itself, establish that a vial contains exactly what it claims in the stated concentration or that it was manufactured, stored and transported under appropriate conditions.
Those questions become particularly important when a product is being injected. Problems involving contamination, concentration or identity are not abstract quality-control issues once the substance is inside a patient.
What “Compounded” Actually Means
Compounded medications have a legitimate role in medicine. A clinician may determine that an individual patient needs a formulation, dose or delivery method that is not available in an appropriate FDA-approved product.
What sometimes gets lost in the marketing is that compounded medications do not go through the same premarket FDA review as approved drugs.
The FDA does not review compounded drugs for safety, effectiveness and manufacturing quality before they are dispensed in the way it reviews an FDA-approved medication. Federal law also governs which bulk drug substances can be used for compounding and under what circumstances.
This became especially visible during the enormous expansion of compounded semaglutide and tirzepatide programs. The FDA has reported adverse events associated with compounded GLP-1 products, including dosing errors involving multi-dose vials. Some patients administered substantially more medication than intended, and some required hospitalization.
That history should not be used to suggest that all compounded medications are unsafe. It does show why good compounding requires more than a prescription. There should be a legitimate clinical reason for using the compounded product, an appropriate pharmacy, understandable dosing instructions, good patient education and someone responsible for follow-up.
Weight Loss Is More Than Sending Someone an Injection
GLP-1 medications have changed obesity medicine because they can produce meaningful weight loss and important metabolic benefits in appropriately selected patients.
They have also created a large commercial market built around getting medication to patients as quickly and conveniently as possible.
Convenience has value. It should not replace medical care.
A thoughtful weight-management program should look beyond whether someone qualifies for a prescription. Depending on the patient, the assessment may include:
- Medical and weight history
- Current medications and contraindications
- Metabolic and cardiovascular risk
- Gallbladder, gastrointestinal and pancreatic history
- Protein intake and nutritional adequacy
- Lean-mass preservation
- Resistance exercise
- Side-effect management
- Dose adjustment
- Plans for maintenance or discontinuation
Body weight alone does not tell the whole story. Losing weight while losing excessive skeletal muscle may be especially problematic in older adults, where strength, mobility and physical resilience are part of the reason for treating obesity in the first place.
At HormoneSynergy Clinic, body-composition assessment and individualized medical evaluation are part of our broader Optimal Aging Assessment. Medication may be part of the plan when appropriate. The prescription is one piece of a much larger clinical picture.
The Financial Relationship Matters
The phrase that stayed with us from the original email was “additional revenue stream.”
There is nothing unusual about money changing hands in healthcare. Medical practices charge for professional services. They employ clinicians and staff. They enter into contracts. Some dispense products or medications where permitted. Physicians also refer patients to outside facilities and specialists every day.
The important question is whether the financial arrangement begins influencing the medical recommendation.
Compensation connected to sending patients to a particular prescribing platform, pharmacy or treatment program deserves careful review. Depending on how an arrangement is structured, issues can include fee splitting, patient steering, corporate-practice restrictions, professional conduct rules, advertising requirements and other state or federal laws.
Cash-pay medicine does not make those concerns disappear.
There is also a simpler question that does not require a law degree to understand:
Would we make the same referral if there were no financial payment attached to it?
That is a useful question for any clinician, wellness business or patient evaluating this type of arrangement.
What Patients Should Ask Before Signing Up
Patients considering an online peptide or compounded weight-loss program should be able to get straightforward answers to some basic questions.
- What medication are you actually prescribing?
- Is the medication FDA-approved for the proposed use?
- If it is compounded, why is a compounded version being used for me?
- Which pharmacy will prepare and dispense it?
- Is that pharmacy operating as a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility?
- What is known about the source of the active pharmaceutical ingredient?
- What human evidence supports the treatment for the reason it is being prescribed?
- Who will manage side effects or complications?
- What follow-up, laboratory testing or clinical monitoring will I receive?
- Is the person or business referring me receiving compensation from my enrollment?
None of these questions is adversarial. They are ordinary questions about medical care, and a reputable clinician should be comfortable answering them.
Our Position: Medicine, Not Marketing
HormoneSynergy Clinic is not opposed to peptides as a class. That would make little medical sense. Some of the most important medications in modern medicine are peptide-based drugs.
We are also not opposed to compounding. There are circumstances in which a properly compounded medication can meet a legitimate individual need that an available commercial product cannot.
Our concern is with the order in which the decisions are made.
A patient should not arrive at a medication because a gym, wellness company, medical practice or online personality discovered a profitable program to sell it through. The decision should come from the patient’s history, examination when appropriate, diagnosis, risks, treatment options and goals.
If a peptide-based or weight-management medication is being considered, there should be a clinical reason for using it. The evidence should be understood. The source should be known. The pharmacy should be appropriate. The patient should understand the risks and dosing. Someone should remain responsible for monitoring what happens after the prescription is written.
Financial relationships should be disclosed rather than hidden behind the language of wellness, optimization or personalized medicine.
Patients trust clinicians with decisions that can affect their health for years. That trust deserves a higher standard than a referral funnel built around recurring revenue.
That is what we mean by Medicine, Not Marketing.
Frequently Asked Questions
Are all peptide medications unsafe?
No. Several important FDA-approved medications are peptides or peptide-based drugs, including insulin and several GLP-1 medications. The concern is not the fact that something is a peptide. The important questions are the evidence for the specific drug and use, how it is prescribed, where it comes from and how the patient is monitored.
Are compounded medications illegal?
No. Compounded medications can be both legal and medically appropriate in specific circumstances. They are not FDA-approved drugs, however, and they do not undergo the same premarket FDA review for safety, effectiveness and manufacturing quality as an approved medication.
Does having a prescription prove that a peptide is safe?
No. A prescription shows that an authorized clinician ordered the product. It does not independently establish the strength of the evidence, the quality of manufacturing, the appropriateness of the source or the long-term safety of the treatment.
What is a “research use only” peptide?
The term generally refers to a substance marketed for laboratory or research purposes rather than as an approved medication for human treatment. A patient should not assume that such a product meets pharmaceutical standards for identity, concentration, sterility or use by injection.
Are telehealth weight-loss programs legitimate?
Some are. Telehealth is simply a way of delivering care, and responsible clinicians can provide excellent care remotely when the situation is appropriate. What matters is the quality of the medical assessment, the source of the medication, the follow-up provided, access to help when problems occur and transparency about financial relationships.
Why does referral compensation matter?
Payment creates the possibility that a recommendation could be influenced by what generates revenue rather than solely by what is best for the patient. That does not mean every compensated relationship is improper. The legality and appropriateness of a particular arrangement depend on how it is structured, who is involved, applicable state law and whether federal healthcare programs are implicated.
References
- U.S. Food and Drug Administration: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
- U.S. Food and Drug Administration: FDA’s Concerns With Unapproved GLP-1 Drugs Used for Weight Loss
- U.S. Food and Drug Administration: Dosing Errors Associated With Compounded Injectable Semaglutide
- U.S. Food and Drug Administration: Bulk Drug Substances Used in Compounding Under Section 503A
This article is part of the HormoneSynergy® Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging.
Return to the Longevity Medicine Guide →